In a recent trial of crenolanib in patients with relapsed or refractory AML harbouring FLT3 mutations, the overall response rate was 31% in patients that had received prior FLT3 TKI treatment and 39% in FLT3 TKI naïve patients [177]. Here, FLT3 is linked to acute myeloid leukemia.